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mDITORIAL COMMENT
troke and Pacing Mode:
s Pacing Mode Important?*
harles R. Kerr, MD, FRCPC, FACC
ancouver, Canada
inus node disease, atrioventricular conduction disease, atrial
brillation, and stroke all have markedly increased incidence in
he elderly. Thus, there is frequently an overlap of these
onditions. Many patients with pacemakers develop atrial
brillation (1–3), and many patients with atrial fibrillation have
oncomitant sinus node dysfunction and receive pacemakers.
his is not surprising in that the sinus node is within the right
trium and is prone to the same pathologic processes as the
tria. Pathologic changes of the atria are the same in settings of
dvanced aging, sinus node dysfunction, and atrial fibrillation,
emonstrating an increase in fibrosis and fat deposition,
articularly in the approaches to the sinus and atrioventricular
odes (4). Because of the high incidence of atrial fibrillation
nd other comorbid conditions of the elderly, such as diabetes,
ypertension, and great vessel atherosclerosis, patients with
acemakers would be expected to have a high incidence of
troke.
See page 1617
“Physiologic” pacing has been considered to be a mode of
acing that preserves the normal atrioventricular activation
equence, that is, atrial-based pacing. Dual-chamber
DDD) pacing is most commonly used in North America
nd is required for patients with atrioventricular conduction
isease. Atrial pacing alone (AAI) can be used only in those
ith normal atrioventricular conduction, that is, sinus node
isease. In North America, AAI mode is uncommonly used
ut is favored in several European Countries, such as
enmark. Recent studies have suggested that DDD pacing
ay not be physiologic in that it alters ventricular activation
equence and hemodynamics (5,6).
Several small and large studies have evaluated the role of
acing mode on outcomes (1–3,7,8). All have included stroke
s part of a combined primary outcome and, alone, as a
econdary outcome. A small Danish study (1,7) compared AAI
ith ventricular pacing (VVI) pacing in patients with sinus
ode disease and showed a reduction in atrial fibrillation and
troke and a delayed reduction in mortality. The Canadian
rial Of Physiologic Pacing (CTOPP) examined patients with
inus or atrioventricular nodal disease and found no reduction
n a combined outcome of cardiovascular mortality or stroke or
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Division of Cardiology, Department of Medicine, University of Britishpolumbia, Vancouver, B.C., Canada.troke alone but a high incidence of atrial fibrillation (5.7%/
ear) and a significant reduction in atrial fibrillation by physi-
logic pacing (relative risk reduction [RRR] 18% at 3 years and
0% at 6 years) (2,8). The Mode Selection Trial (MOST)
xamined patients with sinus node dysfunction only and
howed similar results with no difference in the primary
ombined outcome of mortality or stroke (3). Again, there was
high incidence of atrial fibrillation, both before pacing (50%)
nd in follow-up (8.8%/year) with a significant reduction in
ncidence by DDD pacing mode (RRR 21%).
The current study by Greenspon et al. (9) in this issue of
he Journal examined the population of patients who in-
urred a stroke in the MOST study cohort. Compared with
istorical data from patients with sinus node disease, they
howed a very low rate of stroke (90 of 2,010 total patients),
.2% at 1 year and 4.9% at 3 years. Over the mean follow-up
f 33.1 months, there was no significant difference in the
ate of stroke between the group with VVI pacing mode
4.9%) compared with the group with DDD mode (4%).
he RRR of 18% was not statistically significant.
This study provides a valuable contribution in its ability
o evaluate the factors at implant that were associated with
ubsequent stroke. After multivariable analysis, previous
troke and systemic embolism, hypertension, Caucasian
ace, and New York Heart Association functional class
II/IV heart failure were associated with an increased risk of
troke. Pacing mode was not associated with risk of stroke.
trial fibrillation after randomization also was associated
ith a significantly increased stroke risk.
Antithrombotic therapy was monitored. At baseline, 46%
f the patients in the study were on aspirin, and 23% were
n warfarin. In follow-up, new development of atrial fibril-
ation was “closely associated” with introduction of warfarin
p  0.001). Evaluation of the 1,204 patients who never
eceived warfarin showed that previous stroke or transient
schemic attack and age were the only significant variables
hat were associated with increased risk of stroke.
This study shows some predictable and some unexplained
esults. First, the rate of stroke was low. The incidence of
troke in CTOPP was even lower at 1.1%/year. Both of
hese studies are in stark contrast to previous studies of the
inus node population, both in observational studies (10,11),
here risks of stroke were up to 10%/year and in Andersen’s
rospective study, where stroke rate was 3.5%/year (1,7).
he low rate of stroke is likely explained by increased use of
ntithrombotic therapy in CTOPP and MOST that were
onducted after trials convincingly showed the benefits of
ntithrombotic therapy in atrial fibrillation. The current
tudy documents the appropriate increased use of warfarin
n those patients who developed atrial fibrillation.
The stroke risk in this study and CTOPP is close to that
xpected in a general population of this age. The Framingham
ohort demonstrates an incidence of stroke of 8.4 per 1,000 in
en and 6.1 per 1,000 in women age 65 to 74 years and 16.2er 1,000 in men and 13.5 per 1,000 in women age 75 to 84
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Editorial Comment May 5, 2004:1623–4ears (12). One might expect a higher stroke rate in a paced
opulation because of the high prevalence of risk factors such
s hypertension, atrial fibrillation, diabetes, and underlying
eart disease. The increased treatment of risk factors and use of
ntithrombotic therapy, particularly in a trial setting, may
educe the risk back to that of the general population.
There are some surprising findings from this study that
ay be the result of the relatively small number of patients
ho developed stroke and others that are simply mystifying.
he failure to demonstrate significance of known risk
actors for stroke, namely diabetes, smoking history, and
ale gender may be explained by the small numbers (13,14).
he authors did not attempt to explain the paradoxical
nding of increased risk in the Caucasian population. Other
ohorts have shown that non-Caucasian populations have a
igher incidence of stroke. Again, the small numbers in any
ubgroup may explain this finding, but it does bring into
uestion the statistical strength of the other associations.
As demonstrated by the randomized trials of pacing mode,
here is an unequivocal and sustained reduction in the devel-
pment of atrial fibrillation using atrial based pacing modes.
he failure of this to translate into a significant reduction in
troke in CTOPP and MOST may be the result of the
ppropriate use of antithrombotic therapy. However, the result
ay also be the result of inadequate sample size. The Mode
election Trial and CTOPP showed nonsignificant 18% and
2% RRRs of stroke. Neither was powered to detect a
ifference in stroke alone. Meta-analysis of these studies and
he impending United Kingdom Pacing and Cardiovascular
vents study (15) will be important. The ongoing Danish
ulticenter Randomized Study on AAI versus DDD Pacing
n Sick Sinus Syndrome study (16) will evaluate the role of
entricular pacing in the DDD mode by comparing it with
AI pacing. However, even if the combined results of these
tudies show a significant reduction in stroke with physiologic
acing modes, the clinical significance of any reduction is likely
o be small compared with identification of those at risk.
lthough the final verdict on the association of pacing mode
nd stroke is important, identification of patient characteristics
hat may be associated with stroke is likely more so. The
resent study is important in focusing health professionals on
he ongoing risk of stroke in the paced population, particularly
hose with baseline risk factors.
There are several other factors that should be considered
n a discussion of pacemakers and stroke. Detailed diagnos-
ic capabilities of newer pacemakers are able to log episodes
f atrial fibrillation. This may increase the ability to predict
hose at risk of stroke and/or death (17) and use of these
ata to institute antithrombotic therapy should be encour-
ged. Pacing may result in rate smoothing and decrease the
bility of patients to identify symptoms associated with
trial fibrillation. Patients who undergo atrioventricular
odal ablation are largely unable to tell when they are in
trial fibrillation. Therefore, paced patients who have had
trial fibrillation and risk factors for stroke likely should be
n permanent anticoagulant therapy.The present study focuses us on the importance of
dentification of those at risk of stroke in a population of
atients receiving pacemakers. Baseline characteristics are
argely those that predispose to stroke in the general
opulation and development of atrial fibrillation after pace-
aker implantation increases the risk. We can extrapolate
rom this study that it is important to treat modifiable risk
actors and to be vigilant for the development of atrial
brillation, including use of diagnostic data, and to pre-
cribe antithrombotic therapy aggressively as indicated.
eprint requests and correspondence: Dr. Charles R. Kerr,
344, St. Paul’s Hospital, 1081 Burrard Street, Vancouver, B.C.,
anada V6Z 1Y6. E-mail: ckerr@providencehealth.bc.ca.
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